ClinicalTrials.gg
Status unknownNCT02461407Updated Dec 29, 2017

Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)

A Phase 2/3 interventional study of Anlotinib and Placebo in Gastric Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 38 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-29.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2/3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
378
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,184 studies in Stomach Neoplasms with a site in China — 481 open to participants now, 557 under way, 50 of them phase 3. Stomach Neoplasms · China.

Planned enrollment
164th of 881
378 · median 87
Started
2015
with 45 others
Phase 2/3
24 of 1,184
8 open now
Registered
166th of 1,184
by date

Among the 1,184 studies in Stomach Neoplasms with a site in China, this one is the 164th largest by planned enrollment of the 881 interventional ones that give a count, is one of 46 that started in 2015, is one of 24 in phase 2/3, and was the 166th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

481 of the 1,184 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:

476 more — sign in →

All 481 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,184 studies in Stomach Neoplasms with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Gastric Cancer.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated ;
  2. confirmed advanced gastric adenocarcinoma (including Gastroesophageal junction adenocarcinoma) with outside stomach ( 1.1)
  3. Advanced stomach cancer patients who have failed to the or higher line chemotherapy treatment
  4. >=18 years old; PS:0\~1;Estimated >3 months
  5. Main organs function is normal;

Exclusion criteria

Exclusion Criteria:

  1. Patients who have been treated with anlotinib previously;
  2. Patients who have been treated with other VEGFR-TKI small-molecule drugs previously, such as sunitinib, Sorafenib, famitinib, Apatinib, Regorafenib, ect
  3. Patients suffering from other currently or within 5 years, except for cured cervical carcinoma in situ, non-melanoma skin cancers and superficial bladder cancer [ Ta (non-invasive carcinoma), Tis (carcinoma in situ) and T1 (carcinoma invasion into lamina propria) ]
  4. Systemic anti-cancer therapy scheduled 4 weeks prior to assignment or during this study,including cytotoxic therapy,signal transduction inhibitors,immunotherapy(or received mitomycin C within 6 weeks before this study). Extended field radiotherapy(EF-RT) used within 4 weeks prior to assignment or limited field radiotherapy used to assess tumor lesions within 2 weeks prior to assignment;
  5. (4.0) Grade 1 or higher non-remission toxicity induced by any other previous treatments,excluding alopecia and Grade 2 or lower neurotoxicity induced by oxaliplatin;
  6. Patients with a clear tendency of gastrointestinal bleeding;
  7. Patients with factors that could affect oral medication (such as dysphagia,chronic diarrhea etc.)
  8. Patients with pleural effusion or ascites, causing respiratory syndrome (CTCAE Grade 2 or higher dyspnea [Grade 2 dyspnea refers to Shortness of breath with a small amount of activities, affecting Instrumental activities of daily life])
  9. Patients with any severe and/or unable to control diseases;
  10. Patients underwent major surgical treatment,open or significant traumatic injury within 28 days prior to assignment;
  11. Patients with any physical signs of bleeding diathesis or medical history, no matter how serious degree they are; Patients with any CTCAE Grade 3 or higher bleeding events occurred within 4 weeks prior to assignment; Patients with non-healing wounds,ulcers or fractures;
  12. Patients with arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident (including ), deep vein thrombosis and pulmonary embolism;
  13. Patients with drug abuse history and unable to get rid of or Patients with mental disorders
  14. patients with symptoms or symptoms controlled \< 2 months;
  15. Patients participated in other anticancer drug clinical trials within 4 weeks or Patients participating in other clinical trials now;
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
378 participants (estimated)

Study arms

  • Experimental
    Anlotinib

    Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

    Drug: Anlotinib

  • Placebo comparator
    Placebo

    Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

    Drug: Placebo

Interventions

  • Anlotinib p.o. qd

  • DrugPlacebo

    Placebo p.o. qd

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Time frame: From randomization until death (up to 24 months)

Secondary outcomes

  1. Progress free survival (PFS)

    Time frame: each 42 days up to PD or death(up to 24 months)

  2. Objective Response Rate (ORR)

    Time frame: each 42 days up to intolerance the toxicity or PD (up to 24 months)

  3. Disease Control Rate (DCR)

    Time frame: each 42 days up to intolerance the toxicity or PD (up to 24 months)

07

Study locations

28 of 38 sites recruiting
  • The First Affiliated Hospital, Anhui Medical University
    Hefei, Anhui, China
    Recruiting
    • Kangsheng Gu, doctor · Contact
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
    Recruiting
    • Lin Shen, Doctor · Contact
  • The 307th Hospital of Chinese People's Liberation Army
    Beijing, Beijing, China
    Recruiting
    • Jianming Xu, doctor · Contact
    • Jianming Xu, doctor · Principal investigator
  • Chongqing Daping Hospital
    Chongqing, Chongqing 400042, China
    Recruiting
    • Dong Wang, Doctor · Contact
  • Union Hospital of Fujian Medical University
    Fuzhou, Fujian 350001, China
    Recruiting
    • Xiaoyan Lin, Doctor · Contact
  • Fujian Cancer Hospital
    Fuzhou, Fujian, China
    Not yet recruiting
    • Zengqing Guo, doctor · Contact
  • Lanzhou General Hospital
    Lanzhou, Gansu 730070, China
    Recruiting
    • Baihong Zhang, Doctor · Contact
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong 510060, China
    Recruiting
    • Ruihua Xu, Doctor · Contact
  • The People's Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530021, China
    Recruiting
    • Kehe Chen, Doctor · Contact
  • Fourth Hospital of Hebei Medical University Tumor Hospital of Hebei Province
    Shijiazhuang, Hebei 050011, China
    Recruiting
    • Ruixing Zhang, Doctor · Contact
  • Harbin medical university affiliated tumor hospita
    Harbin, Heilongjiang, China
    Recruiting
    • Yanqiao Zhang, Doctor · Contact
  • Henan Province Tumor Hospital
    Luoyan, Henan, China
    Recruiting
    • Xiaobing Chen, Doctor · Contact
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
    Recruiting
    • Yanru Qin, Doctor · Contact
  • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
    Recruiting
    • Tao Zhang, Doctor · Contact
  • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
    Recruiting
    • Shiying Yu, Doctor · Contact
  • Xiangya Hospital Central South University
    Changsha, Hunan 410008, China
    Not yet recruiting
    • Meizuo Zhong, Doctor · Contact
  • The Third Xiangya Hospital Central South University
    Changsha, Hunan 410013, China
    Not yet recruiting
    • Peiguo Cao, Doctor · Contact
  • Hunan Province Tumor Hospital
    Changsha, Hunan, China
    Recruiting
    • Xianli Yin, Doctor · Contact
  • The General Hospital of Nanhua University
    Hengyang, Hunan 421001, China
    Recruiting
    • Wenxiang Dai, Doctor · Contact
  • The First People's Hospital of Changzhou
    Changzhou, Jiangsu 213003, China
    Recruiting
    • Changping Wu, Doctor · Contact
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu, China
    Not yet recruiting
    • Jianwei Lu, doctor · Contact
  • Jiangsu Province Hospital
    Nanjing, Jiangsu, China
    Recruiting
    • Yongqian Shu, doctor · Contact
    • Yongqian Shu, doctor · Principal investigator
  • Nantong Cancer Hospital
    Nantong, Jiangsu, China
    Recruiting
    • Weidong Yao, doctor · Contact
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Recruiting
    • Jianping Xiong, Doctor · Contact
  • The Second Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Not yet recruiting
    • Anwen Liu, Doctor · Contact
  • Jiangxi Cancer Hospital
    Nanchang, Jiangxi, China
    Not yet recruiting
    • Yiye Wan, doctor · Contact
    • Yiye Wan, doctor · Principal investigator
  • Jilin Cancer Hospital
    Changchun, Jilin 132000, China
    Recruiting
    • Ying Chen, Doctor · Contact
  • Liaoning Province Tumor Hospital
    Shenyang, Liaoning, China
    Recruiting
    • Baoli Qin, doctor · Contact
    • Baoli Qin, doctor · Principal investigator
  • Shandong Tumor Hospital
    Jinan, Shandong 250117, China
    Recruiting
    • Changzheng Li, Doctor · Contact
  • Linyi City Tumor Hospita
    Linyi, Shandong, China
    Recruiting
    • Jianhua Shi, Doctor · Contact
  • Fudan University Zhongshan Hospital
    Shanghai, Shanghai 200032, China
    Not yet recruiting
    • Tianshu Liu, Doctor · Contact
  • Shanghai General Hospital
    Shanghai, Shanghai 200080, China
    Not yet recruiting
    • Liwei Wang, Doctor · Contact
  • Cancer Hospital of Fudan University
    Shanghai, Shanghai, China
    Not yet recruiting
    • Jin Li, doctor · Contact
    • Jin Li, doctor · Principal investigator
  • Tangdu Hospital of The fourth Military Medical University
    Xian, Shanxi, China
    Recruiting
    • Jie Min, doctor · Contact
  • Tianjin Medical University Cancer Hospital
    Tianjin, Tianjin, China
    Not yet recruiting
    • Yi Ba, doctor · Contact
    • Yi Ba, doctor · Principal investigator
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin, China
    Recruiting
    • Diansheng Zhong, Doctor · Contact
  • Yunnan Province Tumor Hospital
    Kunming, Yunnan, China
    Recruiting
    • Jian Dong, Doctor · Contact
  • Sir Run Run Shaw Hospital School of Medical,Zhejiang University
    Hangzhou, Zhejiang 310016, China
    Recruiting
    • Hongming Pan, Doctor · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2015 (actual). Primary completion is estimated for Dec 2017, 30 months after the start.

Of 26 phase 2/3 interventional studies under Stomach Neoplasms, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 52. This study's planned 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2015
First posted
Jun 3, 2015
StartActual
Jun 2015
Primary completionEst.
Dec 2017
CompletionEst.
Dec 2017
Last update
Dec 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02461407
Responsible party
Sponsor
First posted
Jun 3, 2015
Start date
Jun 2015
Primary completion
Dec 2017 (estimated)
Completion
Dec 2017 (estimated)
Last update
Dec 29, 2017

Study contacts

Ruihua Xu, Doctor
Contact
xurh@sysucc.org.cn
Shen Lin, Doctor
Contact

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anlotinib

Start the discussion